Association of Triglyceride-glucose Index With Cardiac Hemodynamics

Launched by ASSIUT UNIVERSITY · Jan 19, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to understand how fat levels in the blood, measured by something called the triglyceride-glucose (TyG) index, are related to heart health in people who are obese. The researchers want to find out how common insulin resistance (a condition where the body doesn’t respond well to insulin) is among obese patients. They will also use heart imaging tests, like echocardiograms and electrocardiograms, to check for any early signs of heart problems in patients who don’t have any symptoms yet. Overall, the goal is to see how heart function is connected to the TyG index and to assess cardiovascular risk in these patients.

To participate in this trial, individuals must be over 18 years old and have been classified as obese for at least two years. They will need to provide written consent. However, those with a history of heart failure, certain heart diseases, or who are taking specific medications that can lead to weight gain will not be eligible. Participants can expect to undergo heart tests and monitoring to help researchers gather important information about heart health in relation to obesity. This study is set to take place from January 2023 to January 2024 and aims to contribute valuable insights into the heart health of obese individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The study will include obese patients over two years duration ( Jan 2023 to Jan 2024 )( age above 18 years old ; written consent will be obtained )
• Exclusion Criteria:
• • History of heart failure or patient known to have congenital heart disease, primary or secondary myocardial disease .
• • Medications associated with weight gain . Patients with previous cardiac diseases (arrhythmias - valve disease). patients who have recently used glucocorticoids or antipsychotics. Patients on statins .